Ruben A. Mesa, MD

About Dr. Mesa

Dr. Mesa is a nationally recognized leader in cancer care and a global authority on myeloproliferative neoplasms (MPNs). As Senior Vice President at Atrium Health and President and Executive Director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Dr. Mesa drives the strategic vision and integration of cancer care, research, and education across a growing health system with centers in Charlotte and Winston-Salem, North Carolina. In academic medicine, he serves as Vice Dean for Cancer Programs and holds the prestigious Charles L. Spurr, MD Professorship in Internal Medicine at Wake Forest University School of Medicine.

Throughout his career, Dr. Mesa has been at the forefront of innovation in hematologic malignancies. His pioneering work in MPN research spanning essential thrombocythemia, polycythemia vera, and myelofibrosis has led to meaningful advances in patient outcomes and the development of several therapies that have become standards of care. A prolific researcher and speaker, Dr. Mesa has authored more than 800 medical publications, including over 400 peer-reviewed articles, and has delivered more than 600 invited lectures around the world.

Driven by a mission to improve lives through science, Dr. Mesa continues to lead transformative efforts in cancer research and care delivery, uniting clinical excellence with a global vision for hematologic oncology.

Articles by Ruben A. Mesa, MD

Ruben A. Mesa, MDMyeloproliferative Neoplasms | June 6, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
View More
Ruben A. Mesa, MDUncategorized | June 7, 2024
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
Ruben A. Mesa, MDUncategorized | July 2, 2024
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
Ruben A. Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
Ruben A. Mesa, MDThe HemOnc Pulse Live | June 7, 2024
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
Ruben A. Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
Ruben A. Mesa, MDThe HemOnc Pulse Live | June 7, 2024
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
Naveen Pemmaraju, MDThe HemOnc Pulse Live | July 26, 2024
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
Ruben A. Mesa, MDVideo Insights | June 7, 2024
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Ruben A. Mesa, MDVideo Insights | June 7, 2024
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.